Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
      • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Multiple Sclerosis
      • Systemic Sclerosis
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Disease-Specific Indications and Outcomes

  • AML - Adult
  • AML - Pediatric
  • ALL - Adult
  • ALL - Pediatric
  • MDS
  • CML
  • CLL
  • NHL
  • Hodgkin Lymphoma
  • Multiple Myeloma
  • Severe Aplastic Anemia & Marrow Failure
  • Sickle Cell Disease
  • Immune Deficiency Diseases
  • Inherited Metabolic Disorders
  • Thalassemia
  • Other Diseases
  • Multiple Sclerosis
  • Systemic Sclerosis
Research Spotlight
  • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes

    December 2022

  • Linkage across research databases may provide a more complete understanding of HCT patient outcomes

    December 2022

  • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT

    December 2022

  • Transplant Indications and Outcomes
  • Disease-Specific Indications and Outcomes
  • ALL - Adult
  • Email
  • Print This Page

Related Resources

  • ALL-Pediatric Advances and Outcomes
  • Subscribe to the Latest ALL Research  
  • HCT Guidelines App
  • ALL Outcomes and Trends Data

Patient Resources

  • Transplant and ALL (PDF)
  • Transplant Basics Booklet
  • Transplant Basics Videos

Acute Lymphoblastic Leukemia (ALL) - Adult

Approximately 6,250 cases of acute lymphoblastic leukemia (ALL) are diagnosed annually in the United States, representing about 23% of new acute leukemias. [1]

Advances

Recent research in ALL provides new data for the management of ALL:
  • Patients transplanted in earlier disease stage have better outcomes than patients with advanced disease [2,3]
  • Allogeneic hematopoietic cell transplantation (HCT) is superior to autologous transplantation or chemotherapy for patients with ALL in first complete remission (CR1). The survival advantage is of greater statistical significance for patients with standard-risk ALL than for patients with high-risk ALL [4,5]
  • In the absence of an HLA-matched donor, consider cord blood transplant or autologous HCT for adult ALL in CR1 [6,7]
  • HLA-matched related and unrelated donor allogeneic HCT produces similar survival outcomes [6]
  • Reduced-intensity HCT using HLA-matched unrelated and unrelated donors is feasible and effective in older patients with B-cell acute lymphoblastic leukemia in CR1 [8]

Outcomes

Review outcomes for allogeneic transplantation in adults with ALL below. View additional ALL slides showing demographic data and transplant trends.

Data in this section have been prepared by CIBMTR® (Center for International Blood and Marrow Transplant Research), our research program.

Figure 1: ALL Survival Over Time, Unrelated HCT

ALL Survival Over Time, Unrelated HCT

Download slide "ALL Survival Over Time in Adults, Unrelated HCT"

Figure 2. ALL Survival, Unrelated Marrow HCT, by Disease Status

ALL Survival in Adults, Unrelated Marrow HCT, by Disease Status

Download slide "ALL Survival in Adults, Unrelated Marrow HCT, by Disease Status"

Figure 3. ALL Survival, Unrelated PBSC HCT, by Disease Status

ALL Survival in Adults, Unrelated PBSC HCT, by Disease Status

Download slide "ALL Survival in Adults, Unrelated PBSC HCT, by Disease Status"

Figure 4. ALL Survival, Sibling HCT, Age ≥18 Years, by Disease Status

ALL Survival in Adults, Sibling HCT, Age ≥18 yrs, by Disease Status

Download slide "ALL Survival in Adults, Sibling HCT, Age ≥18 yrs, by Disease Status"

Figure 5. ALL Survival, Unrelated HCT, Age ≥18 Years, by Disease Status

ALL Survival in Adults, Unrelated HCT, Age ≥18 yrs, by Disease Status

Download slide "ALL Survival in Adults, Unrelated HCT, Age ≥18 yrs, by Disease Status"

Referral Timing Guidelines

These guidelines highlight disease categories that include patients at risk for disease progression and who should be referred for a consultation for autologous or allogeneic transplantation. [9]

Transplant Consultation Guidelines: Adult ALL (adult defined as ≥40 years)

High-resolution HLA typing is recommended at diagnosis for all patients

HCT consultation should take place early after initial diagnosis for all patients with AML, including:

  • Primary induction failure
  • Measurable (also known as minimal) residual disease after initial therapy
  • CR1
  • First relapse
  • CR2 and beyond, if not previously evaluated

Download slide (PPT)
View complete Referral Timing Guidelines


 

CAR T Cell Therapy Video for Patients

In this easy-to-understand video, Linda J. Burns, M.D., Vice President, Health Services Research, and Scott Kerwin, R.N., M.N., C.C.R.C., C.C.R.N., Clinical Trial Patient Education Specialist, explain what CAR T cell therapy is, who it may help, what the treatment is like, potential risks and benefits, questions to ask your doctor, and more. 

In this easy-to-understand video, Linda J. Burns, M.D., Vice President, Health Services Research, and Scott Kerwin, R.N., M.N., C.C.R.C., C.C.R.N., Clinical Trial Patient Education Specialist, explain what CAR T cell therapy is, who it may help, what the treatment is like, potential risks and benefits, questions to ask your doctor, and more. View the video and share it with patients and caregivers who are looking for information on CAR T therapy as a treatment option.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29. Access
  2. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007; 110(13): 4576-4583. Access
  3. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111(4): 1827-1833. Access
  4. Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013; 121(2): 339-350. Access
  5. Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer. 2010; 116(14): 3447-3457. Access
  6. Oliansky DM, Larson RA, Weisdorf D, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: Update of the 2006 evidence-based review. Biol Blood Marrow Transplant. 2012; 18(1): 18-36. Access
  7. Marks DI, Woo KA, Zhong X, et al. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: A comparison with allografts from adult unrelated donors. Haematologica. 2014; 99(2): 322-328. Access
  8. Rosko AE, Wang H-L, de Lima M, et al. Reduced-intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia. Am J Hematol. 2017; 92(1): 42-49. Access
  9. NMDP/Be The Match and ASBMT Recommended Timing for Transplant Consultation. Download (PDF)
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright